Protection of immunized and previously infected chimpanzees challenged with Mycoplasma pneumoniae.
Following immunization, peak geometric mean serum metabolism inhibition antibody (MIT) titres were 1:13 and 1:16 for groups of three chimpanzees each that received either the formalin-inactivated OSU-1A or experimental acellular extract vaccine, respectively. Following challenge, the mean titres for chimpanzees given the acellular vaccine peaked at 1:256 in 4 weeks and was 1:48 at 10 weeks. Chimpanzees given the OSU-1A vaccine peaked at 1:80 in 4 weeks and remained at 1:80 at 10 weeks. There was no direct correlation between the serum MIT response and the severity of disease or colonization, and thus the MIT response was not a reliable measurement of protection. The two non-immunized chimpanzees showed significant signs of disease, including cough, pharyngitis, rhinitis, fever and abnormal X-ray findings, for about 5 weeks. The chimpanzees immunized with either vaccine were less colonized and showed far less disease than non-immunized controls. Protection afforded the chimpanzees was similar to that of vaccinees in the human clinical trial given the same OSU-1A vaccine (Wenzel et al., 1977). The two previously infected chimpanzees were most protected against colonization and disease on challenge.
Barile
M F
MF
Laboratory of Mycoplasma, Center for Biologics Evaluation, FDA, Bethesda, MD 20892.
Grabowski
M W
MW
Kapatais-Zoumbois
K
K
Brown
B
B
Hu
P C
PC
Chandler
D K
DK
D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology*; D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology; D007115:Immunization Schedule; D007136:Immunoglobulins / Q000097:blood; D008297:Male; D009177:Mycoplasma pneumoniae / Q000276:immunology* / Q000378:metabolism; D002679:Pan troglodytes; D011019:Pneumonia, Mycoplasma / Q000517:prevention & control*; D015164:Vaccines, Inactivated / Q000276:immunology
D001428:Bacterial Vaccines; D007136:Immunoglobulins; D015164:Vaccines, Inactivated